Skip to main content
Grifols S.A. logo

Grifols S.A. — Investor Relations & Filings

Ticker · GRF ISIN · ES0171996087 LEI · 959800HSSNXWRKBK4N60 MC Manufacturing
Open in API
Filings indexed 684 across all filing types
Latest filing 2025-05-19 Director's Dealing
Country ES Spain
Listing MC GRF

About Grifols S.A.

https://www.grifols.com/en/home

Grifols S.A. is a global healthcare company specializing in the development, production, and marketing of plasma-derived medicines and other biopharmaceutical solutions. As a leading producer of therapies derived from human plasma, the company addresses the needs of patients with chronic, rare, and life-threatening conditions. Its core activities encompass the entire plasma value chain, from collection to the manufacturing of essential protein therapies. In addition to its primary Biopharma division, Grifols provides a comprehensive portfolio of diagnostic solutions for transfusion medicine and clinical laboratories, as well as bio supplies for pharmaceutical and research applications. The company is committed to advancing patient health and well-being through scientific innovation and high standards of quality and safety.

Recent filings

Filing Released Lang Actions
Motivo de la notificación: Persona con Responsabilidad de Dirección
Director's Dealing Classification · 100% confidence The document is explicitly titled "MODELO DE NOTIFICACIÓN DE LAS OPERACIONES DE LAS PERSONAS CON RESPONSABILIDADES DE DIRECCIÓN Y DE LAS PERSONAS ESTRECHAMENTE VINCULADAS CON ELLAS" (Standard Form for Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with Them). This form details transactions (purchases of shares) made by an executive (Consejero Delegado - CEO) of GRIFOLS, S.A. This directly corresponds to the definition of Director's Dealing (insider trades by directors/executives). Reviewing the filing types: - 10-K/IR/ER/AR are financial reports. - CT/IP are call transcripts or presentations. - The document clearly reports personal share transactions by a director/executive. - This matches the definition for Director's Dealing (Code: DIRS).
2025-05-19 Spanish
Motivo de la notificación: Persona con Responsabilidad de Dirección
Director's Dealing Classification · 100% confidence The document is explicitly titled 'STANDARD FORM FOR NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES (PDMR) AND PERSONS CLOSELY ASSOCIATED WITH THEM'. This form details transactions (Compra/Buy) made by an executive (CFO Rahul Srinivasan) in the company's shares. This directly corresponds to the definition of Director's Dealing (insider trades) which is classified under the code DIRS.
2025-05-16 Spanish
FORM 6-K
Regulatory Filings
2025-05-12 English
Grifols anuncia la información financiera del primer trimestre de 2025
Earnings Release Classification · 100% confidence The document is titled "Resultados del primer trimestre de 2025" (First Quarter 2025 Results) and contains detailed financial metrics (Revenue, Adjusted EBITDA, Net Income, Free Cash Flow) for a specific fiscal period (Q1 2025). It explicitly states that Grifols has presented its 'resultados financieros del primer trimestre de 2025' (first quarter 2025 financial results). This content structure—a summary of period performance, key figures, management commentary, and guidance reaffirmation—is characteristic of an Earnings Release (ER) or a comprehensive Interim/Quarterly Report (IR). Since the text provides substantial detail, including a full financial table comparing Q1 2025 to Q1 2024, it goes beyond a simple 'Earnings Release' (ER) which usually contains only key highlights. It aligns best with the definition of an Interim/Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a year. The document is clearly the report itself, not just an announcement of its publication (RPA). Q1 2025
2025-05-12 Spanish
FORM 6-K
Regulatory Filings
2025-05-06 English
Como continuación de la Información Privilegiada presentada por Grifols el 31 de marzo de 2025, Grifols informa que hoy BaFin ha aprobado la publicación del documento de oferta presentado por su fi...
M&A Activity Classification · 100% confidence The document is a formal communication from Grifols, S.A., labeled as 'INFORMACIÓN PRIVILEGIADA' (Privileged Information) under Spanish law (Article 226 of Law 6/2023). The core content announces that the German financial authority (BaFin) has approved the publication of a tender offer document for the delisting of Biotest AG shares. This involves a takeover bid and subsequent acquisition of shares by a subsidiary. This activity directly relates to a merger proposal or takeover bid. Reviewing the definitions: - 10-K, AR, IR, ER, MRQ are financial reporting types. - CT, IP are presentation/transcript types. - DIRS, DVA, DIV, SHA, POS relate to share transactions or voting results. - The most fitting category is 'M&A Activity' (Code: TAR), which covers 'Announcements and documents related to merger proposals or takeover bids.' The document explicitly discusses a 'public acquisition offer' (oferta pública de adquisición) for the exclusion of listing.
2025-05-06 Spanish

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.